Metformin targets multiple signaling pathways in cancer

Metformin, an inexpensive and well-tolerated oral agent commonly used in the first-line treatment of type 2 diabetes, has become the focus of intense research as a candidate anticancer agent. Here, we discuss the potential of metformin in cancer therapeutics, particularly its functions in multiple s...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Yong, Yi, Yanhua, Liu, Yang, Liu, Xia, Keller, Evan T., Qian, Chao-Nan, Zhang, Jian, Lu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270304/
https://www.ncbi.nlm.nih.gov/pubmed/28126011
http://dx.doi.org/10.1186/s40880-017-0184-9
_version_ 1782501164446646272
author Lei, Yong
Yi, Yanhua
Liu, Yang
Liu, Xia
Keller, Evan T.
Qian, Chao-Nan
Zhang, Jian
Lu, Yi
author_facet Lei, Yong
Yi, Yanhua
Liu, Yang
Liu, Xia
Keller, Evan T.
Qian, Chao-Nan
Zhang, Jian
Lu, Yi
author_sort Lei, Yong
collection PubMed
description Metformin, an inexpensive and well-tolerated oral agent commonly used in the first-line treatment of type 2 diabetes, has become the focus of intense research as a candidate anticancer agent. Here, we discuss the potential of metformin in cancer therapeutics, particularly its functions in multiple signaling pathways, including AMP-activated protein kinase, mammalian target of rapamycin, insulin-like growth factor, c-Jun N-terminal kinase/mitogen-activated protein kinase (p38 MAPK), human epidermal growth factor receptor-2, and nuclear factor kappaB pathways. In addition, cutting-edge targeting of cancer stem cells by metformin is summarized.
format Online
Article
Text
id pubmed-5270304
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52703042017-02-01 Metformin targets multiple signaling pathways in cancer Lei, Yong Yi, Yanhua Liu, Yang Liu, Xia Keller, Evan T. Qian, Chao-Nan Zhang, Jian Lu, Yi Chin J Cancer Review Metformin, an inexpensive and well-tolerated oral agent commonly used in the first-line treatment of type 2 diabetes, has become the focus of intense research as a candidate anticancer agent. Here, we discuss the potential of metformin in cancer therapeutics, particularly its functions in multiple signaling pathways, including AMP-activated protein kinase, mammalian target of rapamycin, insulin-like growth factor, c-Jun N-terminal kinase/mitogen-activated protein kinase (p38 MAPK), human epidermal growth factor receptor-2, and nuclear factor kappaB pathways. In addition, cutting-edge targeting of cancer stem cells by metformin is summarized. BioMed Central 2017-01-26 /pmc/articles/PMC5270304/ /pubmed/28126011 http://dx.doi.org/10.1186/s40880-017-0184-9 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Lei, Yong
Yi, Yanhua
Liu, Yang
Liu, Xia
Keller, Evan T.
Qian, Chao-Nan
Zhang, Jian
Lu, Yi
Metformin targets multiple signaling pathways in cancer
title Metformin targets multiple signaling pathways in cancer
title_full Metformin targets multiple signaling pathways in cancer
title_fullStr Metformin targets multiple signaling pathways in cancer
title_full_unstemmed Metformin targets multiple signaling pathways in cancer
title_short Metformin targets multiple signaling pathways in cancer
title_sort metformin targets multiple signaling pathways in cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270304/
https://www.ncbi.nlm.nih.gov/pubmed/28126011
http://dx.doi.org/10.1186/s40880-017-0184-9
work_keys_str_mv AT leiyong metformintargetsmultiplesignalingpathwaysincancer
AT yiyanhua metformintargetsmultiplesignalingpathwaysincancer
AT liuyang metformintargetsmultiplesignalingpathwaysincancer
AT liuxia metformintargetsmultiplesignalingpathwaysincancer
AT kellerevant metformintargetsmultiplesignalingpathwaysincancer
AT qianchaonan metformintargetsmultiplesignalingpathwaysincancer
AT zhangjian metformintargetsmultiplesignalingpathwaysincancer
AT luyi metformintargetsmultiplesignalingpathwaysincancer

Ejemplares similares